Free Trial

Bill Maughan Analyst Performance

Analyst at Canaccord Genuity Group

Bill Maughan is a stock analyst at Canaccord Genuity Group in the medical sector, covering 1 publicly traded companies. Over the past year, Bill Maughan has issued 1 stock ratings, including and hold recommendations. While full access to Bill Maughan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Bill Maughan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
1 Last 0 Years
Buy Recommendations
0.00% 0 Buy Ratings
Companies Covered
1 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy0.0%0 ratings
Hold100.0%1 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Hold recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
1 company

Bill Maughan, an analyst at Canaccord Genuity Group, currently covers 1 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
1 company
100.0%

Bill Maughan of Canaccord Genuity Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
100.0%

Bill Maughan's Ratings History at Canaccord Genuity Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
8/5/2025Downgrade$8.52$8.60Hold